argenx SE (MEX:ARGXN) EPS (Basic): MXN441.11 (TTM As of Mar. 2026)


MEX:ARGXN argenx SE MEX:ARGXN
63 GF Score
Price MXN13,000.67
GF Value MXN20,951.12
! 5 Warning Signs
View Full Analysis

What is argenx SE EPS (Basic)?

argenx SE MEX:ARGXN 63 EPS (Basic) is MXN441.11 as of Mar. 2026. GuruFocus rates MEX:ARGXN with a GF Score™ of 63/100 and a GF Value™ of MXN20,951.12. The stock has 5 warning signs investors should review.

argenx SE's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was MXN106.39. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN441.11.

argenx SE's EPS (Diluted) for the three months ended in Mar. 2026 was MXN99.54. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN410.11.

argenx SE's EPS without NRI for the three months ended in Mar. 2026 was MXN102.11. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 400.41.

During the past 12 months, argenx SE's average EPS without NRIGrowth Rate was 22.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, argenx SE's highest 3-Year average EPS without NRI Growth Rate was 19.00% per year. The lowest was -107.70% per year. And the median was -40.30% per year.

argenx SE  (MEX:ARGXN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

argenx SE EPS (Basic) Related Terms

argenx SE EPS (Basic) Historical Data

* Premium members only.

The historical data trend for argenx SE's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE EPS (Basic) Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -163.91 -254.42 -87.59 290.31 379.56

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.87 75.69 102.91 156.11 106.39
MEX:ARGXN
63GF Score
argenx SE MEX:ARGXN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

argenx SE's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(23263.995-0)/61.295
=379.54

argenx SE's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(6599.968-0)/62.057
=106.35

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN441.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of MXN441.11 mean?
argenx SE (MEX:ARGXN) has a EPS (Basic) of MXN441.11 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on argenx SE and its competitors.
Is argenx SE's EPS (Basic) too high?
argenx SE's current EPS (Basic) is MXN441.11. Overall, argenx SE has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does argenx SE's EPS (Basic) compare to VRTX and REGN?
argenx SE's EPS (Basic) of MXN441.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on argenx SE and its competitors. argenx SE's current EPS (Basic) is MXN441.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
argenx SE (MEX:ARGXN) has a current EPS (Basic) of MXN441.11. The stock's GF Value™ is MXN20,951.12, compared to a current price of MXN13,000.67 — trading 37.9% below its estimated fair value. The current EPS (Basic) is MXN441.11. argenx SE's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For argenx SE (MEX:ARGXN), the current EPS (Basic) is MXN441.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (MEX:ARGXN) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of MXN13,000.67 is trading 37.9% below its estimated GF Value™ of MXN20,951.12.

Key valuation signals for MEX:ARGXN:

  • EPS (Basic): MXN441.11
  • GF Value™: MXN20,951.12 vs. price of MXN13,000.67 (37.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the MEX:ARGXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
63GF Score

Get the complete analysis for MEX:ARGXN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN13,000.67
Price
MXN20,951.12
GF Value